Table 2.
Differentially expressed canonical pathways (IPA) and upregulated KEGG pathways (GENECODIS) in ‘Good’ and ‘Bad’ PDAC
| Goodversuscontrol | Badversuscontrol | |||
|---|---|---|---|---|
|
Canonical pathwaysa |
P-value |
Upregulated genesc |
P-value |
Upregulated genesc |
| Integrin signalling |
5.62E-7 |
RAC1, RAC2, ITGB4, ITGB5, ITGA6, ACTN1, MAP2K2, GSK3B, PPP1R12A, ARF1, ACTG2 |
4.79E-6 |
RAC1, ITGA2, ITGA3, ITGA6, ITGB1, ITGB4, ITGB5, ITGB6, ACTN1, ARF1 |
| Ephrin receptor signalling |
0.00002 |
RAC1, RAC2, EPHA2, EPHB2, EFNA4, EFNB2, MAP4K4, MAP2K2, STAT3, RHOA, ADAM10, VEGFA |
0.00001 |
RAC1, EFNA5, EFNB2, EPHA2, EPHB4, STAT3, ADAM10, FGF1, VEGFA, PDGFC |
| Molecular mechanism of cancer |
0.00063 |
RAC1, RAC2, CCND1, MAP2K2, TGFβ1, GSK3B, BRCA1, CDH1, BMP2, SMAD6, BAX, CTNNB1 |
|
|
| P53 signalling |
0.00089 |
TP53, PIK3C2A, RAC1, BAX, BIRC5, SERPINB5, GSK3B, BRCA1 |
0.02757 |
PRKDC, RAC1, BAX, CCND1, BIRC5, SERPINB5, CTNNB1, CDK2 |
| Wnt/β-catenin |
0.00550 |
RAC2, CSNK1A1, CSNK1E, SOX9, TGFβ1, SOX4, LRP5, CTNNB1, WNT10A |
0.00323 |
CSNK1A1, TGFβ1, DKK1, DKK3, WNT5A, WNT10A, SOX4, SOX11, TCF7L2, TCF3 |
| Pancreatic adenocarcinoma |
|
|
0.00776 |
JAK1, RAC1, STAT3, CCND1, BIRC5, VEGF, TGFβ1, ERBB2, CDK2 |
| PI3K/AKT Signaling |
0.00933 |
RAC1, RAC2, JAK1, MAP2K2, PPP2R5 |
|
|
|
KEGG pathwaysb |
|
|
|
|
| P53 Signaling |
2.20E-12 |
TP53, CDKN6, CCND1, CDK1, CDK2, SFN |
3,03E-8 |
CDK1, CDK2, BAX, SERPINB5, CCND1, SFN |
| Wnt signalling |
2,67E-07 |
WNT10A, CTNNB1, CTBP1, LRP5, TCF7L2, FZD8, GSK3B, PPP3R1, RAC1 |
0.00011 |
WNT5A, WNT10A, DKK1, DVL1, CTNNB1, CSNK1A1, CSNK1E, LRP5, RAC1, TCF7L2 |
| Pancreatic cancer |
3.00E-6 |
TGFβ1, RAC1, JAK1, VEGFA, ERBB2, STAT3,TP53, RAC2 |
0.00001 |
RAC1, TGFβ1, TGFα, VEGFA, ERBB2, STAT3, RAD51 |
| NOTCH signalling |
2.40E-6 |
JAG1, HES1, CTBP1, CTBP2, ADAM10 |
0.00012 |
DVL1, HES1, CTBP1, ADAM10 |
| MAPK signalling |
0.00015 |
FGFR2, TGFβ1, MAP2K5, MAP2K2, MAP2K3, MAP2K7, RAC1, DUSP10, DUSP3 |
|
|
| Hedgehog signalling | 0.00836 | CSNK1E, BMP2, GSK3B, CSNK1A1 | ||
aIPA was performed on respectively 2.806 (good) and 1.692 (bad) differentially expressed probe sets (with entry in the Ingenuity Knowledge Base; http://www.ingenuity.com). The most significant networks, functions and canonical pathways are listed.
b KEGG analysis was performed on respectively 2.033 and 1.285 probesets upregulated in the good and bad PDAC samples using GENECODIS.
c A selection of upregulated genes contributing to the pathways, is given.